Oligonucleotides News and Research

RSS

Oligonucleotides are short sequences of nucleotides (RNA or DNA), typically with twenty or fewer bases. Automated synthesizers allow the synthesis of oligonucleotides up to 160 to 200 bases.

Lorus Therapeutics allowed Canadian patent to protect anticancer drugs

Lorus Therapeutics today announced that its wholly owned subsidiary, GeneSense Technologies Inc., has been allowed a patent by the Canadian Patent Office entitled "Antitumor Antisense Sequences Directed Against R1 and R2 Components of Ribonucleotide Reductase."

10 Nov 2004

STAT3 protein could lead to new ways to prevent skin cancer

Scientists at The University of Texas M. D. Anderson Cancer Center have identified a protein that serves as a master regulator of skin cancer - a finding that could lead to new ways to prevent skin cancer before it starts.

4 Nov 2004

Researchers discover that DNA fragments destroy melanoma cells

Researchers at Boston University School of Medicine have discovered that small DNA fragments or oligonucleotides that resemble the telomere (chromosome end), also called T-oligos, can cause human melanoma cells to undergo extensive apoptosis (cell death), while surviving melanoma cells become more differentiated and therefore less aggressive.

1 Sep 2004

New service-oriented laboratory focused on bioanalysis and pharmacokinetics

Oregon Health & Science University researchers will more quickly move benchtop discoveries toward drug discoveries with the help of a new, service-oriented laboratory focused on bioanalysis and pharmacokinetics.

11 Aug 2004

Total global market for oligonucleotides is likely to grow from USD 340.0 million in 2003 to USD 776.0 million in 2010

Poised on the brink of phenomenal growth, the oligonucleotides market offers a plethora of opportunities to the enterprising investor. Recent analysis by Frost & Sullivan estimates that the total global market for oligonucleotides is likely to grow from USD 340.0 million in 2003 to USD 776.0 million in 2010.

9 Aug 2004

Surprising differences in the DNA of normal cells from different people

A new study by Michael Wigler’s group at Cold Spring Harbor Laboratory has, in collaboration with researchers from Karolinska Institutet, revealed surprising differences in the DNA of normal cells from different people.

23 Jul 2004

Market research 'World RNAi Markets: Current and Future Outlook'

Gene silencing by RNAi has now been identified as a crucial technology for target validation and therapeutics. By targeting and interfering with messenger RNA (mRNA), RNAi technology blocks the expression of the proteins implicated in disease progression.

19 Jul 2004